Welcome to our dedicated page for KalVista Pharmaceuticals news (Ticker: KALV), a resource for investors and traders seeking the latest updates and insights on KalVista Pharmaceuticals stock.
KalVista Pharmaceuticals, Inc. (KALV) is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of small molecule protease inhibitors. The company's mission is to bring innovative treatments to patients suffering from a range of diseases, with a strong focus on hereditary angioedema (HAE) and diabetic macular edema (DME).
KalVista's core business revolves around developing small molecule plasma kallikrein inhibitors. Their product portfolio includes:
- Hereditary Angioedema (HAE) inhibitors: These inhibitors are designed to prevent and treat the debilitating attacks associated with HAE, a disorder characterized by severe swelling in various body parts.
- Diabetic Macular Edema (DME) inhibitors: These inhibitors target plasma kallikrein, which is implicated in the retinal vascular permeability that leads to DME, a common complication of diabetes that can cause vision loss.
The company operates primarily in the United States and has made significant strides in its research and development efforts. Recent achievements include successful clinical trials, strategic partnerships, and securing funding to advance their pipeline projects.
KalVista maintains a robust financial condition, supported by several rounds of funding and strategic investments. The company prioritizes transparency and regularly updates stakeholders on its progress through press releases and public disclosures.
Investors looking to keep abreast of the latest developments and financial performance of KalVista Pharmaceuticals can find comprehensive updates and reports on their official website and through stock market platforms like StockTitan.
KalVista Pharmaceuticals has promoted Ben Palleiko to President, expanding his role to lead business and commercial growth following a
KalVista Pharmaceuticals has announced a registered direct offering of 9.484 million shares at $6.00 per share and 182,470 prefunded warrants at $5.999, totaling approximately $58 million in gross proceeds. The offering is set to close on December 28, 2022, pending customary conditions. Proceeds will fund clinical trials, commercial sales development, research, and working capital, enabling operations funding into 2025. The shares are offered under an effective shelf registration statement with the SEC, enhancing liquidity for future projects and developments.
KalVista Pharmaceuticals (NASDAQ: KALV) has completed its Phase 1 clinical trial for an orally disintegrating tablet formulation of sebetralstat, with promising results published in the Journal of Medicinal Chemistry and Xenobiotica. Despite terminating the Phase 2 KOMPLETE trial for KVD824 due to safety concerns, the company remains focused on advancing its Phase 3 KONFIDENT trial for sebetralstat, expecting data in H2 2023. Financially, KALV recorded no revenue for Q2, with a net loss of $22.3 million. Cash on hand is $122.3 million, down from $166.2 million, primarily due to operating expenses.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announced the granting of inducement stock options for 2,000 shares to a newly-hired employee, effective December 1, 2022. The options have an exercise price of $5.34, matching the closing stock price on the grant date. Vesting occurs in stages, with a quarter vesting after one year and the remainder in monthly installments over three years. KalVista focuses on developing innovative therapies for conditions like hereditary angioedema and diabetic macular edema, with ongoing clinical trials for sebetralstat and KVD001.
KalVista Pharmaceuticals (NASDAQ: KALV) presented two impactful posters at the 2022 American College of Allergy, Asthma & Immunology meeting, revealing the significant effects of hereditary angioedema (HAE) attacks on patients' mental health and daily activities. Over half of HAE patients reported limitations in functions due to the condition. The second poster highlighted the treatment burden related to on-demand parenteral therapies, noting common adverse drug reactions. CEO Andrew Crockett emphasized the need for less traumatic treatment options, leading to KalVista’s focus on developing oral therapies for HAE.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announced participation in investor conferences, including the Stifel 2022 Healthcare Conference on November 15, 2022, and the Jefferies London Healthcare Conference on November 17, 2022. Live webcasts of both presentations will be accessible on KalVista's website, with an audio archive available for 30 days post-event. KalVista focuses on developing oral, small molecule protease inhibitors for conditions like hereditary angioedema (HAE) and diabetic macular edema (DME), with ongoing clinical trials for its lead candidate, sebetralstat.
KalVista Pharmaceuticals (NASDAQ: KALV) announced the granting of inducement stock options to a newly hired employee. A total of 2,000 shares were issued at an exercise price of $5.10 per share, equivalent to the closing price on November 1, 2022. The options will vest over four years, with 25% vesting after one year and the remainder in monthly increments. This move aligns with Nasdaq Listing Rule 5635(c)(4) and aims to incentivize the new employee's ongoing contribution to the company.
KalVista Pharmaceuticals (NASDAQ: KALV) announced positive Phase 1 results for an orally disintegrating tablet (ODT) formulation of its lead compound, sebetralstat, aimed at treating hereditary angioedema (HAE). The trial involved 36 healthy adult volunteers and indicated a similar pharmacokinetic profile between the ODT and the existing film-coated tablets. The company plans to develop the ODT further and aims for its availability post-launch of sebetralstat. Data from the ongoing Phase 3 KONFIDENT trial is expected in H2 2023, supporting a planned NDA filing in H1 2024.
KalVista Pharmaceuticals announced new data on sebetralstat, published in the Journal of Medicinal Chemistry and Xenobiotica. The research highlights its effectiveness as an on-demand treatment for hereditary angioedema (HAE), showcasing high selectivity against human serine proteases and rapid absorption characteristics, essential for patient needs. Sebetralstat has progressed to Phase 3 KONFIDENT trials, indicating significant advancement towards clinical application. CEO Andrew Crockett expressed optimism about sebetralstat's promise for HAE treatment.
KalVista Pharmaceuticals has announced a significant leadership change, appointing
FAQ
What is the current stock price of KalVista Pharmaceuticals (KALV)?
What is the market cap of KalVista Pharmaceuticals (KALV)?
What does KalVista Pharmaceuticals specialize in?
What diseases does KalVista target with its products?
What is a plasma kallikrein inhibitor?
Where does KalVista Pharmaceuticals operate?
How can investors stay updated on KalVista's progress?
Has KalVista formed any strategic partnerships?
What are KalVista's recent achievements?
What is hereditary angioedema (HAE)?
What is diabetic macular edema (DME)?
What financial condition is KalVista in?
